This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Prostate Cancer Daily
UroAlerts - Prostate Cancer Daily
Prostate Cancer
Intermittent hormone therapy for prostate cancer inferior to continuous therapy
Exelixis initiates COMET-1 pivotal trial focused on overall survival in men with advanced prostate cancer
Meet the Expert - Judd W. Moul
AUA 2012 - European Randomized Study of Screening for Prostate Cancer (ERSPC): An update after 11 years of follow-up - Slide Presentation
AUA 2012 - The absence of goal setting in the dialogue between metastatic prostate cancer (mCRPC) patients and their physicians: An opportunity for shared decision making? - Another Perspective
AUA 2012 - Does long-term aspirin use lower serum PSA levels? – Results from the Duke Prostate Center - Session Highlights
AUA 2012 - Unilateral prostate cancer: Analysis of predictors in search and Duke Prostate Center databases - Session Highlights
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer - Abstract
Investigative clinical study on prostate cancer part VIII: Prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy - Abstract
AUA 2012 - mCRPC in focus: Androgen biosynthesis inhibition and metastatic castration-resistant prostate cancer, clinical insights from the Clinical Industry Theater presentation by Judd Moul, MD
AUA 2012 - Neurostimulation treatment for overactive bladder: An evaluation of cost effectiveness data - Slide Presentation
Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse - Abstract
Urologists' self-referral for pathology of biopsy specimens linked to increased use and lower prostate cancer detection - Abstract
Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat - Abstract
Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: Implications for the effect of LH on the adrenal glands - Abstract
A workspace-orientated needle-guiding robot for 3T MRI-guided transperineal prostate intervention: Evaluation of in-bore workspace and MRI compatibility - Abstract
Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial - Abstract
Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy - Abstract
AUA 2012 - Making sense of all the new options: Pragmatic considerations in CRPC - Slide Presentation
Scanometric MicroRNA array profiling of prostate cancer markers using spherical nucleic acid-gold nanoparticle conjugates - Abstract
Visit the UroToday Prostate Cancer Section
Update Your Email Preferences
|
Unsubscribe
UroToday - 1741 Eighth Street - Berkeley, CA USA 94710 -
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free